Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients

A legfontosabb adatok

Ki végzi
Uriach Consumer Healthcare
Hol
Spanyolország4 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
533 fő vett részt
Kezdés
2022. szept. 22.
Befejezés
2023. nov. 22.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • carboxymethyl β-glucan
A regiszteradat frissítve
2024. január 10.

Ki vehet részt

Életkor
25 év – 65 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Egyéb feltételek

  • TREATMENT GROUP
  • INCLUSION:
  • Women aged between 25 and 65 years (inclusive)
  • Histological cervical cytology results reported as ASCUS, LSIL/CIN1, with a positive cervical PCR determination for high-risk HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
  • Patients currently undergoing treatment with the combination of carboxymethyl B-glucan and polycarboxyl (for at least 15 days prior to study initiation)
  • Capable of reading and comprehending the patient information sheet and the informed consent form
  • Willing to participate in the study and sign the informed consent form; EXCLUSION:
  • Cervical cytology indicating suspected invasive cervical cancer
  • Ongoing or recent pregnancy terminated within six weeks of the study commencement
  • Clinically significant immunodeficiency-linked pathology
  • Active or terminated immunosuppressive treatment within six months of study entry. Specifically, in the case of corticosteroids, women will be excluded if they are currently or recently receiving corticosteroid treatment (defined as within two weeks prior to study entry) or if they have undergone two or more cycles of corticosteroids at doses equal to or greater than 20 mg/day of Prednisone (or equivalent) orally or parenterally for at least one week's duration in the year prior to study entry
  • Undiagnosed abnormal genital bleeding
  • Total hysterectomy
  • Documented history of cervical pathology caused by HPV
  • Contraindications to the use of the combination of Carboxymethyl B-glucan and polycarboxyl, or known allergies to any of its components; CONTROL GROUP; INCLUSION:
  • Women aged between 25 and 65 years (inclusive)
  • Histological cervical cytology results reported as ASCUS, LSIL/CIN1, with a positive cervical PCR determination for high-risk HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
  • Patients not currently undergoing treatment for HPV
  • Capable of reading and comprehending the patient information sheet and the informed consent form
  • Willing to participate in the study and sign the informed consent form; EXCLUSION:
  • Cervical cytology indicating suspected invasive cervical cancer
  • Ongoing or recent pregnancy terminated within six weeks of the study commencement
  • Clinically significant immunodeficiency-linked pathology
  • Active or terminated immunosuppressive treatment within six months of study entry. Specifically, in the case of corticosteroids, women will be excluded if they are currently or recently receiving corticosteroid treatment (defined as within two weeks prior to study entry) or if they have undergone two or more cycles of corticosteroids at doses equal to or greater than 20 mg/day of Prednisone (or equivalent) orally or parenterally for at least one week's duration in the year prior to study entry
  • Undiagnosed abnormal genital bleeding
  • Total hysterectomy
  • Documented history of cervical pathology caused by HPV
  • Concurrent participation in a clinical study of an investigational drug that could interfere with the current study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prospective, Controlled, Multicentre, Real Clinical Practice Study. Effectiveness of Carboxymethyl β-Glucan treatment in high-risk HPV+ patients

A vizsgálat 2 csoportja

  • CONTROL GROUP

    For the duration of the study, standard clinical practice will be followed wait and see strategy, without administering carboxymethyl-b-glucan treatment.

  • TREATMENT GROUP

    For a period of three months, patients will be administered once daily treatment with Carboxymethyl β-glucan and Polycarbophil

    Kezelés: carboxymethyl β-glucan

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Efficacy and Safety of the Local Treatment of Carboxymethyl Beta-glucan and Polycarbophil in Patients With Normal Cytology/ASCUS/LSIL (CIN1) With HPV+ PCR Determination
A regiszteradat frissítve
2024. január 10.